1 January 2024 in Infection and Drug Resistance
Background: Diabetes is a growing health concern globally. Poorly managed diabetes may result in diabetic foot ulcers (DFU), which can become a source of chronic infection known as diabetic foot infections. The increasing trend of diabetes in Uganda speaks to the potential for diabetic foot ulcers which may eventually become infected and their attendant impact on the quality of life of diabetic patients. This review assesses the microbial diversity of DFUs in Uganda, aiming to guide treatment and identify research gaps. Main Body of the Abstract: We searched PubMed, Scopus and Embase for studies conducted in Uganda that reported isolating microorganisms from diabetic foot ulcers. Following the preferred reporting items for systematic reviews and meta-analysis (PRISMA), we included two eligible studies that reported isolating 122 bacteria spread across eleven (11) species using swab samples and conventional culture methods. Significant isolates included World Health Organization priority pathogens including: Enterobacter specie, Staphylococcus aureus, Klebsiella pneumoniae, and Acinetobacter specie. Methicillin resistant Staphylococcus aureus (MRSA) constituted 33.3% of Staphylococci species and 26% of all bacterial isolates while extended-spectrum beta-lactamase producing Escherichia coli and Klebsiella specie constituted 14.29% of total microbial isolates. Most bacteria showed susceptibility to Imipenem, Vancomycin, Ciprofloxacin, and Clindamycin, but resistance to Cotrimoxazole and Ampicillin was noted. Short Conclusion: We conclude that data on the microbiology of DFUs in Uganda is scarce; however, the bioburden of DFUs in the country is similar to those in other parts of the world, and MRSA poses a challenge to antibiotic therapy. Consequently, the continued use of swab samples and conventional culture and sensitivity methods may limit the isolation, identification, and presentation of other important isolates. We recommend characterization of bacterial isolates to better understand their genetic makeup, and the development of a national guideline for managing diabetic foot infections.
1 January 2026 in Diabetes, Metabolic Syndrome and Obesity
Background: Metformin is the cornerstone of type 2 diabetes mellitus (T2DM) management but has been linked to vitamin B12 deficiency (VB12D), a condition with potential hematological, neurological, and neuropsychiatric consequences. Despite this association, little is known about its burden in Uganda. This study aimed to determine the prevalence, associated factors, and clinical outcomes of VB12D among patients with T2DM on metformin at Hoima Regional Referral Hospital (HRRH). Methods: A hospital-based cross-sectional study was conducted involving 257 adult T2DM patients on metformin attending the diabetic clinic at HRRH between February and April 2024. Data were collected using interviewer-administered questionnaires and chart reviews. Serum vitamin B12 levels were measured using an electrochemiluminescence immunoassay. Deficiency was defined as levels < 150 pg/mL. Data were analyzed using STATA v17. Logistic regression was used to determine factors independently associated with VB12D. Results: The prevalence of VB12D among participants was 10.1%. Independent factors associated with VB12D included metformin use ≥ 10 years (AOR 3.94; 95% CI 1.34– 11.56), daily dose of 2000 mg (AOR 4.32; 95% CI 1.47– 12.67), and elevated glycated hemoglobin (AOR 2.63; 95% CI 1.08– 6.41). Clinical outcomes significantly associated with VB12D included peripheral neuropathy (76.9% vs 46.8%, p=0.005) and neuropsychiatric symptoms (50.0% vs 28.6%, p=0.042). Conclusion: Vitamin B12 deficiency is relatively common among T2DM patients on metformin at HRRH. Longer duration and higher dosage of metformin, as well as poor glycemic control, were significantly associated with deficiency. Peripheral neuropathy and neuropsychiatric manifestations were more frequent among those deficient. Routine screening for VB12D, especially in patients on long-term and high-dose metformin, is recommended to reduce morbidity.